NCT07188246View on ClinicalTrials.gov

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

January 31, 2029

Conditions
Breast CancerBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer InvasiveBreast Cancer Triple Negative
Interventions
RADIATION

Radiation

Stereotactic body radiation therapy to the breast

DRUG

Pembrolizumab (KEYTRUDA®)

Two injections

Trial Locations (2)

N6A 4V2

St. Joseph's Health Care London, London

Unknown

London Regional Cancer Program, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER